Investigational drug · Phase 3
DTT106
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Prostatic Hyperplasia, Benign, Erectile Dysfunction.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 20, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "DTT106"
First trial start
2025
Feb 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
- EMS1
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DTT106", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostatic Hyperplasia, Benign
- Erectile Dysfunction
Approved drugs for the same conditions: Erectile dysfunction · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "DTT106" as an intervention, largest first.
- Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic HyperplasiaPivotal-lookingNot yet recruiting
EMSIndustry
NCT06264414 · 262 participants (planned) · Start Feb 2025 · Primary completion Jun 2026
Drug: DTT106; Dutasteride-Tamsulosin · For: Prostatic Hyperplasia, Benign; Erectile Dysfunction
Sites: Hortolândia, Brazil
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.